tert-butyl(4-chloro-3-trifluoromethylphenyl)amine | 1631962-34-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: tert-butyl(4-chloro-3-trifluoromethylphenyl)amine
• 英文别名: N-tert-butyl-4-chloro-3-(trifluoromethyl)aniline
• CAS: 1631962-34-9
• 化学式: C₁₁H₁₃ClF₃N
• 分子量: 251.679
• InChiKey: LVRUAJCVGHHHJO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  叔丁基三氯乙酰亚胺酯 、 2-氯-5-氨基三氟甲苯 在 copper(II) bis(trifluoromethanesulfonate) 作用下， 以 硝基甲烷 为溶剂， 反应 2.0h， 以99%的产率得到tert-butyl(4-chloro-3-trifluoromethylphenyl)amine
  参考文献：
  名称：

  使用 2,2,2-三氯乙酰亚胺叔丁基酯在温和条件下铜催化芳香胺的 N-叔丁基化

  摘要：

  已经发现，在室温下，在 2,2,2-三氯亚胺酸叔丁酯存在下，多种芳香胺可以方便地进行铜催化的 N-叔丁基化反应。

  DOI：

  10.1055/s-0033-1339107

文献信息

• SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE
  申请人：Smith D. Charles

  公开号：US20070032531A1

  公开（公告）日：2007-02-08

  The invention relates to compounds, pharmaceutical compositions thereof, and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferative disease, inflammatory disease, or angiogenic disease,

  这项发明涉及化合物、其药物组合物以及抑制鞘氨醇激酶并治疗或预防过度增殖性疾病、炎症性疾病或血管生成性疾病的方法。
• PYRROLOTRIAZINE COMPOUNDS AS KINASE INHIBITORS
  申请人：Fink Brian E.

  公开号：US20090048244A1

  公开（公告）日：2009-02-19

  The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.

  本发明提供公式I化合物及其药学上可接受的盐。公式I化合物抑制生长因子受体的酪氨酸激酶活性，如HER1、HER2和HER4，因此使它们有用作抗增殖剂。公式I化合物也适用于治疗与通过生长因子受体进行信号转导途径相关的其他疾病。
• Sphingosine Kinase Inhibitors and Methods of Their Use
  申请人：Smith Charles D.

  公开号：US20100137315A1

  公开（公告）日：2010-06-03

  The invention relates to compounds, pharmaceutical compositions thereof, and methods for inhibiting sphingosine kinase and for treating or preventing hyperproliferative disease, inflammatory disease, or angiogenic disease.

  该发明涉及化合物，其制药组合物以及抑制鞘氨醇激酶和治疗或预防过度增生性疾病，炎症性疾病或血管生成性疾病的方法。
• Amino Compounds for Treatment of Complement Mediated Disorders
  申请人：Achillion Pharmaceuticals, Inc.

  公开号：US20150239894A1

  公开（公告）日：2015-08-27

  Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof, wherein R 12 or R 13 on the A group is an amino substituent (R 32 ) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.

  本文提供了公式I或其药学上可接受的盐或组合物所组成的抑制补体因子D的化合物、使用方法和制备过程，其中A组上的R12或R13是氨基取代基（R32）。所述抑制剂靶向因子D并在替代性补体途径的早期和关键点上抑制或调节补体级联反应，并减少因子D调节经典和凝集素补体途径的能力。本文所述的因子D抑制剂能够减少过度激活补体，这与某些自身免疫性、炎症性和神经退行性疾病以及缺血再灌注损伤和癌症有关。
• HYDROXYINDOLE CARBOXYLIC ACID BASED INHIBITORS FOR ONCOGENIC SRC HOMOLOGY-2 DOMAIN CONTAINING PROTEIN TYROSINE PHOSPHATASE-2 (SHP2)
  申请人：INDIANA UNIVERSITY RESEARCH & TECHNOLOGY CORPORATION

  公开号：US20160102054A1

  公开（公告）日：2016-04-14

  Inhibitors of protein tyrosine phosphatases are disclosed. The inhibitors include hydroxyindole carboxylic acids having a linker and an amine scaffold that are potent inhibitors of Src homology 2-domain containing protein tyrosine phosphatase-2.

  本发明公开了蛋白酪氨酸磷酸酶的抑制剂。这些抑制剂包括具有连接基和胺支架的羟基吲哚羧酸，它们是Src同源2-含有蛋白酪氨酸磷酸酶的有效抑制剂。